Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07032662 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 27 words
  2. Study sites: 141 to 142v12
  3. Site details revised at 1 of 141 sitesv11
  4. Trial sites expanded: 138 → 141 locationsv10
  5. Trial sites expanded: 135 → 138 locationsv9
Show 7 earlier versionsHide 7 earlier versions
  1. Site details revised at 1 of 135 sitesv8
  2. Interventions: IMVT-1402 (Drug), Placebo (Drug) to Imeroprubart (Drug), Placebo (Drug)
    • Study description revised
    • Site details revised at 6 of 135 sites
    • Study title revised
    v7
  3. Site details revised at 10 of 135 sitesv6
  4. Study sites: 134 to 135v5
  5. Site details revised at 15 of 134 sitesv4
  6. Site details revised at 15 of 134 sitesv3
  7. Site details revised at 30 of 134 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
Trial Details
NCT Number NCT07032662
Lead Sponsor Immunovant Sciences GmbH
Conditions
(from sponsor)		 Chronic Inflammatory Demyelinating Polyneuropathy
Related terms Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Enrollment 162 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov